Brief: Clover Biopharmaceuticals Plans To License In Mid- To Late-Stage Vaccine Product In H2 Of 2023
23/08/2023 02:43
Aug 23 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* PLANS TO LICENSE IN A MID- TO LATE-STAGE VACCINE PRODUCT
IN
SECOND HALF OF 2023
* IN FOLLOWING MONTHS, COMPANY WILL FOCUS ON DELIVERING OUR
ADIMFLU-S (QIS) SALES TARGET
* HY ADJUSTED PROFIT RMB674.5 MILLION VERSUS LOSS RMB1.07
BILLION
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune